HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

quininib

has antiangiogenic activity; structure in first source

Also Known As:

2-(2-(quinolin-2-yl)vinyl)phenol

Networked: 5 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenols: 677
        quininib: 5
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - quininib: 5

Experts

1.	Butler, Clare T: 3 articles (10/2020 - 10/2016)
2.	Kennedy, Breandán N: 3 articles (10/2020 - 10/2016)
3.	O'Sullivan, Jacintha: 3 articles (10/2020 - 10/2016)
4.	Kennedy, Susan A: 2 articles (10/2020 - 06/2019)
5.	Conroy, Emer: 2 articles (06/2019 - 10/2016)
6.	Gallagher, William M: 2 articles (06/2019 - 10/2016)
7.	Alvarez, Yolanda: 1 article (01/2022)
8.	Kennedy, Breandán: 1 article (01/2022)
9.	Mahon, Niamh: 1 article (01/2022)
10.	O'Brien, Justine: 1 article (01/2022)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 10/14/2016 - "Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer." 06/04/2019 - "1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours." 10/02/2020 - "Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors."
2.	Neoplasms (Cancer) 01/01/2022 - "CysLT1 antagonists, quininib and 1,4-dihydroxy quininib, alter cancer hallmarks of primary and metastatic UM cell lines in vitro. " 06/04/2019 - "Here, Q8, quininib (Q1) and five structural analogues were assayed for anti-tumorigenic effects in pre-clinical cancer models. " 10/02/2020 - "1,4-dihydroxy quininib alone, and in combination with Bevacizumab or FOLFOX significantly reduced TIE-2 expression which is involved in the promotion of tumor vascularization. " 01/01/2022 - "The quininib series highlighted the potential of CysLT receptors as therapeutic targets for retinal vasculopathies (e.g., neovascular age-related macular degeneration, diabetic retinopathy, and diabetic macular edema) and ocular cancers (e.g., UM)."
3.	Uveal melanoma 01/01/2022 - "1,4-dihydroxy quininib modulates the secretome of uveal melanoma tumour explants and a marker of oxidative phosphorylation in a metastatic xenograft model." 01/01/2022 - "Quininib acts as a cysteinyl leukotriene (CysLT) receptor antagonist, revealing new roles of these G-protein-coupled receptors in developmental angiogenesis of the eye and unexpectedly in uveal melanoma (UM). "
4.	Pathologic Neovascularization 01/01/2022 - "In vivo, quininib drugs reduce pathological angiogenesis and retinal vascular permeability in rodent models. "
5.	Macular Edema 01/01/2022 - "The quininib series highlighted the potential of CysLT receptors as therapeutic targets for retinal vasculopathies (e.g., neovascular age-related macular degeneration, diabetic retinopathy, and diabetic macular edema) and ocular cancers (e.g., UM)."

Related Drugs and Biologics

1.	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)
2.	Retinaldehyde (Retinal)
3.	Bevacizumab (Avastin)
4.	cysteinyl-leukotriene